Pharmacotherapy of Giardiasais: Past, Present & Future

Total Page:16

File Type:pdf, Size:1020Kb

Pharmacotherapy of Giardiasais: Past, Present & Future Gastroenterology & Hepatology International Journal ISSN: 2574-8009 Pharmacotherapy of Giardiasais: Past, Present & Future Gupte S* and Gupte N Review Article Department of Pharmacology, Lady Hardinge Medical College and Hospitals, India Volume 1 Issue 2 Department of Pediatrics, Mamata Medical College and General and Superspeciality Received Date: July 29, 2016 Published Date: September 8, 2016 Hospitals, India *Corresponding author: Suraj Gupte, Professor and Head, Postgraduate Department of Pediatrics, Mamata Medical College and General and Superspeciality Hospitals, Khammam, 507002, Telangana, India. Email: [email protected] Abstract Objective: In view of the scattered information about pharmacotherapy of the common protozoal infestation in the English medical literature, this update aims at providing a state-of-the-art review concerning the drug therapy of giardiasis. Resource and Design: Systemic literature review augmented with authors’ own first-hand experience in dealing with pediatric giardiasis spread over quite a few decades. Salient Features: Most subjects with giardiasis, a neglected disease, respond favorably to the available drugs though frequency of recurrences is high. However, immunocompromised persons pose the problem of less satisfactory response to routine pharmacotherapy, often necessitating a change in the drug regimen. In some cases, therapy needs to be complemented with other measures aimed at safeguarding against reinfection and passing infection to family members, peers and coworkers. Currently, albendazole, metronidazole, tinidazole and nitazoxanide stand out as the most acceptable amongst the plethora of drugs for giardiasis. Conclusion: Choosing an appropriate agent with attention to rationality in therapy plus preventive measures is mandatory to meet the challenge of giardiasis. Keywords: Alkbendazole; Giardiasis; Firazolidine; L. giardia; Mepacrine; Metronidazole; Nitazoxanide; Ornidazole; Secnidazole; Tinidazole Introduction Infection with L. giaredia is a common cause of immunocompromised hosts, should be treated is catching morbidity, especially in resource-limited communities [1- up fast [9,10]. 5]. In a nutshell, all symptomatic cases must be offered the Conventionally speaking, only symptomatic giardiasis benefit of effective pharmacotherapy. Additionally, all needs drug therapy [6-10]. The view that even asymptomatic cases likely to spread infection to asymptomatic giardiasis (after all it is set to become immunocompromised contacts, pregnant women and symptomatic sooner or later), especially in subject with cystic fibrosis should be treated. Family members and close contacts of asymptomastic but Pharmacotherapy of Giardiasais: Past, Present & Future Gastroenterol Hepatol Int J 2 Gastroenterology & Hepatology International Journal positive for L. giardia need to be treated lest they reifect once only, yields a cure rate of around 85%. lid and others. Some experts advocate treatment of symptopm- transient gastrointestinal ADRs may be encountered. free cases on the plea that they are potentional risk to others and likely to become symptomatic at some point of Ornidazole time [9,10]. A multitude of antigiardial drugs are available A relatively new 5-nitroimidazole, administered 2g in [11]. adults and 40 mg/kg in children as a single dose once only, ornidazole is very effective in giardiasis. It is better Conventional Antigiardial Drugs tolerated by children compared to the earlier 5- nitroimidazoles [2,5]. ADRs include unpleasant taste, Mepacrine (Atabrine, Quinacrine) decreased appetite and dark urine. Related to mefloquine, it is, in all probability, the oldest among the antigiardial drugs administered in a dose of Furazolidine 100 mg TID in adolescents and 5 to 8 mg/kg/day (3 A nitrofuran, it has a potent antigiardial activity, acting divided doses) in children for 5 to 7 days. It gives by gradual inhibition of monoamine oxidase [2,5] excellent clinical as well as parasitological cure of the Dose is 100 mg 3 or 4 times a day in adults and 6-8 magnitude of 90-95%. mg/kg/day (3-4 divided doses) over a period of 7-10 days. Its use has become obsolete on account of its bitter Usual ADRs include gastrointestinal upset, staining of the taste, poor tolerance (nausea, vomiting and abdominal urine and mild drug rash. cramps) and toxicity (transient yellow discoloration/ staining of the skin, sclera and urine). Moreover, it is no Albendazole longer freely available. Presently, its use is restricted to symptomatic giardiasis refractory to modern drugs. A benzimidazole, structurally related to mebendazole, albendazole is effective against many infestations, Metronidazole including giardiasis [2,5]. Albendazole, given for 5 days, is as effective as metronidazole for the treatment of Over recent decades, metronidazole, a first generation giardiasis with the advantage of fewer ADRs.Dose is 400 nitroimidazole, has occupied a pride of the place as an mg (200 mg for < 2 years) daily for 5 days. In view of the antigiardial agent. It continues to be the most commonly safety, effectiveness, and low cost, and anti-helmintic employed antigiardial therapy. action albendazole, is now considered an acceptable Though quite a safe agent, an unpleasant metallic taste alternative for metronidazole in the treatment of owing to its excretion in the saliva is often irritating to the giardiasis. patient. Paromomycin The dose is 200-300 mg TID in adults and 15 to 20 mg/kg/day in children for 5 to 7 days. A cure rate of A non-absorbable oral aminoglycoside, it is less around 90% is expected [5]. Of late, resistance to effective than other antigiardial agents. Its plus point is metronidazole is being increasingly reported. that it is the only available antigiardial agent that can be safely given to a pregnant woman with symptomatic Tinidazole giardiasis [5]. Dose is 500 mg BID for 5-10 days. It acts by interfering with ribosomal subunits. Efficacy rate is This 5-nitroimidazole, given in a dose of 2 g in adults around 60-70%. It has minimal absorption with minimal and 50-60 mg/kg once only or 20 mg/kg/day for 5 days, side effects yields a higher clinical and parasitological cure rate compared to metronidazole [2,5]. Relatively New Antigiardial Nitazoxanide: Nitazoxanide, a prodrug of niclosamide, is Usually, mild gastrointestinal disturbance is the only the latest entry as an alternative agent for treatment of ADR. giardiasis [12]. Given 500 mg twice daily in adolescents and adults and 7-10 mg/kg/dose twice daily in pediatric Secnidazole subjects for 3 days (Table 1), it yields excellent results. This, a long-acting 5-nitroimidazole, given in a dose of 2 ADRs include abdominal pain, diarrhea, vomiting and g for adults and 30 mg/kg for children as a single dose, headache. Gupte S and Gupte N. Pharmacotherapy of Giardiasais: Past, Present & Copyright© Fiore M Gupte S and Gupte N Future. Gastroenterol Hepatol Int J 2016, 1(2): 000108. 3 Gastroenterology & Hepatology International Journal Age Group Dose shows comparable results [12]. However, nitazoxanide is also effective against E. hitolytica as well as some Adults and adolescents 500 mg BID helminthes, its course spreads over just 3 days compared 1-3 yr 100 mg BID to 5-7 days in case of metronidazole and is better 4-11 yr 200 mg BID tolerated. 12 yr and beyond 500 mg BID Currently Recommended Drug Regimens Table 1: Dosage of nitazoxanide in terms of age groups. Table 1 presents a summary of the currently Notably, nitazoxanide, is generally well tolerated and recommended drug regimens for giardiasis. can be used in cases refractory to metronidazole treatment. Tizoxanide, its active metabolite, is eight times Dosage in Dosage in more active than metronidazole against susceptible Drug adults/adolescents children strains. Even against against resistant isolates, its activity 200-400 mg TID x 7- 15 mg/kg/day is double that of metronidazole. The Food and Drug Metronidazole Administration (FDA) has included it as one of the first 10 days x 7-10 days 50-60 mg/kg line treatments for giardiasis. When giardiasis and Tinidazole 2 g once only cryptosporidiosis coexist in a immunocompetent person, once only nitazoxanide is strongly recommended as it is effective 40 mg/kg once Ornidazole 2 g once only against both [13]. only 7-10 Herbal Therapy for Giardiasis mg/kg/day in 2 divided doses x In early 1971, a chance observation suggested that 3 days berberine—an alkaloid from the Indian medicinal plant Berberis aristata—may be an effective antigiardial 1-3 yr: 100 mg BID x 3 days drug. [14] A controlled study suggested that berberine, Nitazoxanide 500 mg BID x 3 days administered orally in a dose of 10 mg/kg/day for ten 4-11 yr: 200 days, resulted in satisfactory parasitological cure, mg/kg BID x 3 comparable to that obtained with other established days antigiardial drugs (quinacrine hydrochloride [mepacrine], >12 yr: 500 mg furazolidone, and metronidazole). Not much has been BID x 3 days done in subsequent decades on the efficacvy of <2 yr: 200 mg berbereine in giardiasis, except for an occasional OD x 5 days Albendazole 400 mg OD x 5 days investigation or two that provided encouraging outcome >2 yr 400 mg [15]. OD x 5 days 6-8 mg/kg/day Relative Efficacy of Antigiardial Drugs 100 mg QID x 10 in 4 divided Furazolidine days doses x 5 - Undoubtedly, mepacrine tops the list in case of clinical 7days and parasitological cure. But, on account of its ADRs and Table 1: Dosage of recommended drug regimens for difficult-to-obtain status, its use is limited to difficult and giardiasis [1-3,6,7]. resistant cases. Among the commonly employed drugs, in case of a Drug Therapy in Refractory/Recurrent single dose therapy, best outcome is with tinidazole Giardiasis followed by ornidazole . Secnidazole, though effective as a single dose therapy, gives a somewhat lower cure rate. The following options are available for refractory or recurrent giardiasis, problem common in For multidose therapy, cure rate with metronidazole, immunocompromised states:- tinidazole, albendazole and nitazoxanide is of a similar Simultaneous therapy of family members with order.
Recommended publications
  • Expert Review 2
    2021 Expert Committee on Selection and Use of Essential Medicines Application review I.1 Albendazole, mebendazole and praziquantel for the indication of treatment of (item number) taeniid cestode cysts Does the application adequately ☒ Yes address the issue of the public health ☐ need for the medicine? No ☐ Not applicable Comments: The larval stages of three taeniid cestode parasites, Echinococcus granulosus, Echinococcus multilocularis and Taenia solium, produce cysts in humans that are of medical relevance. The diseases caused by these parasitic cysts are called cystic echinococcosis (CE), alveolar echinococcosis (AE), and cysticercosis (being neurocysticercosis (NCC) the most common form) respectively, and they are recognised by WHO as neglected tropical diseases. NCC is mainly a disease of poverty that predominantly affects rural populations in Africa, Asia and Latin America. Access to diagnostic and treatment, to better manage epilepsy and other NCC is a challenge for the people affected in these communities due to the availability and costs of specialised diagnostic and care. Stigma and social discrimination also mean that many people try to “hide” the disease. Briefly summarize the role of the The only real options for treatment of CE are albendazole (ALB) and Mebendazole proposed medicine(s) relative to other (MEB). ALB is the drug of choice as it has better bioavailability. ALB is also preferred to therapeutic agents currently included in MEB, because MEB requires a higher dose and a higher pill burden, for example, an the Model List, or available in the adult patient would require 8 tablets/day of MEB compared with 2 tablets/day ALB. market. ALB and praziquantel ( PZQ) are the only drugs used for the antiparasitic treatment of NCC.
    [Show full text]
  • ALBENDAZOLE (Extrapolation to All Ruminants)
    European Medicines Agency Veterinary Medicines and Inspections EMEA/MRL/865/03-FINAL June 2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE ALBENDAZOLE (Extrapolation to all ruminants) SUMMARY REPORT (3) 1. Albendazole is a benzimidazole carbamate, used for the treatment of gastrointestinal infestations with roundworms, lungworms and tapeworms and adult flukes of Fasciola hepatica. Albendazole is currently entered into Annex I of Council Regulation (EEC) No. 2377/90 in accordance with the following table: Pharmacologically Marker residue Animal MRLs Target Other active substance(s) species tissues provisions Albendazole Sum of albendazole Bovine, 100 µg/kg Muscle sulphoxide, ovine 100 µg/kg Fat albendazole sulphone 1000 µg/kg Liver and albendazole 2- 500 µg/kg Kidney amino sulphone 100 µg/kg Milk expressed as albendazole 2. In reviewing the availability of endo- and ectoparasiticides for sheep and goats, albendazole was considered for extrapolation from bovine and ovine species to all ruminants. The considerations and criteria leading to the identification of albendazole are described in the Position Paper Regarding Availability of Veterinary Medicines – Extrapolation of MRLs (EMEA/CVMP/457/03-FINAL). 3. The scientific justification for this extrapolation was assessed in accordance with the Notes for Guidance on Risk Analysis Approach for Residues of Veterinary Medicinal Products in Food of Animal Origin (EMEA/CVMP/187/00-FINAL) and on the Establishment of Maximum Residue Limits for Minor Animal Species (EMEA/CVMP/153a/97-FINAL). 4. In setting the ADI in the original assessment of albendazole, the data summarised on the paragraphs below were considered. 5. The mode of action of albendazole is by binding strongly with the tubulin in the cells of nematodes.
    [Show full text]
  • Efficacy and Tolerability of Quinacrine Monotherapy and Albendazole Plus Chloroquine Combination Therapy in Nitroimidazole-Refractory Giardiasis: a Tropnet Study
    Klinik für Infektiologie & Spitalhygiene Efficacy and tolerability of quinacrine monotherapy and albendazole plus chloroquine combination therapy in nitroimidazole-refractory giardiasis: a TropNet study Andreas Neumayr, Mirjam Schunk, Caroline Theunissen, Marjan Van Esbroeck, Matthieu Mechain, Manuel Jesús Soriano Pérez, Kristine Mørch, Peter Sothmann, Esther Künzli, Camilla Rothe, Emmanuel Bottieau Journal Club 01.03.21 Andreas Neumayr Background on giardia treatment: • 1st-line treatment: 5-nitroimidazoles: metronidazole (1957), tinidazole, ornidazole, secnidazole • cure rate of 5NIs in 1st-line treatment: ~90% • in the last decade, an increase of 5NI-refractory giardia cases has been observed in travel medicine clinics across Europe: Hospital for Tropical Diseases, London: 2008: 15% --> 2013: 40% 70% of 5NI-refractory cases imported from India • 2nd-line treatment: effectiveness of a 2nd round with a 5NI: ~17% alternative drugs: albendazole, mebendazole, nitazoxanide, quinacrine, furazolidone, chloroquine, paromomycin 2012 TropNet member survey: 53 centres use 39 different treatment regimens, consisting of 7 different drugs in mono- or combination-therapy in various dosages and durations JC 01.03.21 Nabarro LE et al. Clin Microbiol Infect. 2015;21:791-6. • by 2013, there were only 13 reports of 2nd-line therapy for giardiasis (8 case series, 5 individual case reports): n=110 Cure rates Albendazole 6/32 18.7% Paromomycin 5/17 29.4% Nitazoxanide 2/5 40.0% Albendazole + 5-NI 42/53 79.2% Quinacrine 19/21 90.5% Quinacrine + 5-NI 14/14 100% Quinacrine + Paromomycin 2/2 100% • 2013: TropNet "GiardiaREF" study kick-off: Study on efficacy and tolerability of two 2nd-line regimens in nitroimidazole-refractory giardiasis: Quinacrine JC 01.03.21 Meltzer E et al.
    [Show full text]
  • Study Assessing Prices, Availability and Affordability of Children's
    Study assessing prices, availability and affordability of children’s medicine in Chhattisgarh, India Part of the Better Medicine for Children project Authors Dr Antony KR Virendra Jain Puni Kokho Dr Kamlesh Jain The salient findings and views expressed in this report are solely those of the authors. Please direct correspondence to the authors: ([email protected], [email protected] [email protected], [email protected]). This publication does not necessarily represent the decisions or policies of the World Health Organization. ii Contents Acknowledgements ........................................................................................... v Abbreviations ................................................................................................... vi Executive summary ......................................................................................... vii Medicine availability .............................................................................................vii Medicine costs ................................................................................................... viii Affordability of standard treatment regimens ........................................................... ix Price components survey ...................................................................................... ix Conclusion .......................................................................................................... x 1. Introduction .................................................................................................
    [Show full text]
  • Valbazen ® (Albendazole)
    ® (albendazole oral suspension) Broad-Spectrum Dewormer Oral Suspension for Use in Cattle, Sheep, and Goats for removal and control of liver flukes, tapeworms, stomach worms (including 4th stage inhibited larvae of Ostertagia ostertagi), intestinal worms, and lungworms in cattle and sheep and for the treatment of adult liver flukes in nonlactating goats Active Ingredient Albendazole ............................. 11.36% (equivalent to 113.6 mg/mL) 1 L/33.8 fl oz (1 qt 1.8 fl oz) Approved by FDA under NADA # 110-048 40029175 ® (albendazole oral suspension) Broad-Spectrum Dewormer Oral Suspension for Use in Cattle, Sheep, and Goats for removal and control of liver Indications: flukes, tapeworms, stomach worms (including 4th stage inhibited larvae of Ostertagia Cattle and sheep: Valbazen is a broad-spectrum anthelmintic effective in the removal ostertagi), intestinal worms, and lungworms in cattle and sheep and for the treatment and control of liver flukes, tapeworms, stomach worms (including 4th stage inhibited of adult liver flukes in nonlactating goats larvae of Ostertagia ostertagi ), intestinal worms, and lungworms as indicated below. Active Ingredient: Goats: For the treatment of adult liver flukes in nonlactating goats. Albendazole .......................................................... 11.36% (Equivalent to 113.6 mg/mL) Parasite Cattle Sheep Goats Adult Liver Flukes Fasciola hepatica Fasciola hepatica, Fascioloides magna Fasciola hepatica Heads and Segments Moniezia benedeni, M. expansa Common Tapeworm (Moniezia expansa), Fringed Tapeworm of Tapeworms (Thysanosoma actinioides) Adult and 4th Stage Brown Stomach Worm, including 4th stage Brown Stomach Worm (Ostertagia circumcincta, Marshallagia Larvae of Stomach inhibited larvae (Ostertagia ostertagi), marshalli), Barber Pole Worm (Haemonchus contortus), Small Worms Barber Pole Worm (Haemonchus Stomach Worm (Trichostrongylus axei) contortus, H.
    [Show full text]
  • Safety and Efficacy of Nitazoxanide-Based Regimen for the Eradication of Helicobacter Pylori Infection: a Systematic Review and Meta-Analysis
    Original Article Gastroenterol Res. 2020;13(6):260-268 Safety and Efficacy of Nitazoxanide-Based Regimen for the Eradication of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis Umair Iqbala, g, Harshit S. Kharaa, Daud Akhtarb, Yirui Huc, Hafsa Anward, Khwaja F. Haqe, Hafiz U. Siddiquif, Marika K. Bergenstocka, Matthew J. Shellenbergera Abstract eradication regimens revealed a pooled eradication rate of 85% (95% CI: 69-94%) without heterogeneity. In a subgroup analysis, highest Background: Helicobacter pylori (HP) is the most common cause of eradication rates were achieved with levofloxacin, doxycycline, nita- gastritis worldwide. Clarithromycin-based triple therapy or bismuth- zoxanide and proton pump inhibitor with a pooled eradication rate of based quadruple therapy is usually considered the first-line treatment, 92% (88-95%). however with around 30% failure rate for both regimens. Drug re- Conclusion: Nitazoxanide-based regimen is safe and effective in the sistance of clarithromycin and metronidazole is a growing concern eradication of HP infection. It is also successful as a salvage therapy in some parts of the world. Therefore, there is a need for effective in patients who have failed prior treatments. eradication regimen for HP. Nitazoxanide, a bactericidal thiazolide antibiotic, has been shown to be effective in HP infection. We con- Keywords: Nitazoxanide; Helicobacter pylori; Eradication regimen; ducted a systematic review and meta-analysis to evaluate the efficacy Meta-analysis of nitazoxanide-based regimen for the eradication of HP. Methods: We have searched PubMed, Embase, Ovid Medline and Cochrane library database from inception to December 9, 2020 to identify studies that utilized nitazoxanide in the treatment regimen Introduction for HP eradication.
    [Show full text]
  • Albendazole: a Review of Anthelmintic Efficacy and Safety in Humans
    S113 Albendazole: a review of anthelmintic efficacy and safety in humans J.HORTON* Therapeutics (Tropical Medicine), SmithKline Beecham International, Brentford, Middlesex, United Kingdom TW8 9BD This comprehensive review briefly describes the history and pharmacology of albendazole as an anthelminthic drug and presents detailed summaries of the efficacy and safety of albendazole’s use as an anthelminthic in humans. Cure rates and % egg reduction rates are presented from studies published through March 1998 both for the recommended single dose of 400 mg for hookworm (separately for Necator americanus and Ancylostoma duodenale when possible), Ascaris lumbricoides, Trichuris trichiura, and Enterobius vermicularis and, in separate tables, for doses other than a single dose of 400 mg. Overall cure rates are also presented separately for studies involving only children 2–15 years. Similar tables are also provided for the recommended dose of 400 mg per day for 3 days in Strongyloides stercoralis, Taenia spp. and Hymenolepis nana infections and separately for other dose regimens. The remarkable safety record involving more than several hundred million patient exposures over a 20 year period is also documented, both with data on adverse experiences occurring in clinical trials and with those in the published literature and\or spontaneously reported to the company. The incidence of side effects reported in the published literature is very low, with only gastrointestinal side effects occurring with an overall frequency of just "1%. Albendazole’s unique broad-spectrum activity is exemplified in the overall cure rates calculated from studies employing the recommended doses for hookworm (78% in 68 studies: 92% for A. duodenale in 23 studies and 75% for N.
    [Show full text]
  • Treatment Outcomes with Nitazoxanide in Immunocompetent
    dicine & Me S l u a r ic g e p r o y r T Ali and Kumar, Trop Med Surg 2015, 3:4 Tropical Medicine & Surgery DOI: 10.4172/2329-9088.1000198 ISSN: 2329-9088 Research Article Open Access Treatment Outcomes with Nitazoxanide in Immunocompetent Adults Naive Patients with Cryptosporidiosis; Do We Need Combination Therapy with Paromomycin or Azithromycin? Sajjad Ali1* and Sunil Kumar2 1Chairman Infection Prevention and Control Department, Department of Internal Medicine/Infectious Diseases, Sultan Bin AbdulAziz Humanitarian City Hospital, Riyadh, Saudi Arabia 2Department of Infectious Diseases, Sindh Institute of Urology and Transplantation, Karachi, Pakistan *Corresponding author: Sajjad Ali, Chairman Infection Prevention and Control Department, Department of Internal Medicine/Infectious Diseases, Sultan Bin AbdulAziz Humanitarian City Hospital, Riyadh, Saudi Arabia, Tel: 00966115620000; E-mail: [email protected] Received date: September 16, 2015, Accepted date: October 16, 2015, Published date: October 19, 2015 Copyright: © 2015 Sajjad, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. Abstract Introduction: Human cryptosporidiosis is caused by infection with Cryptosporidium. Nitazoxanide has shown activity against cryptosporidium. The objective of this study is to see treatment outcomes with 7 days of nitazoxanide in immunocompetent adult patients diagnosed with cryptosporidiosis and to consider combination therapy which includes nitazoxanide with paromomycin or azithromycin? Study Design: This cross sectional study was conducted at Sindh Institute of Urology and Transplantation, Karachi Pakistan. Patients were not enrolled with prior diagnosis of cryptosporidiosis and/or had taken Nitazoxanide, Paromomycin or Azithromycin in last 4 weeks prior their diagnosis.
    [Show full text]
  • Comparative Genomics of the Major Parasitic Worms
    Comparative genomics of the major parasitic worms International Helminth Genomes Consortium Supplementary Information Introduction ............................................................................................................................... 4 Contributions from Consortium members ..................................................................................... 5 Methods .................................................................................................................................... 6 1 Sample collection and preparation ................................................................................................................. 6 2.1 Data production, Wellcome Trust Sanger Institute (WTSI) ........................................................................ 12 DNA template preparation and sequencing................................................................................................. 12 Genome assembly ........................................................................................................................................ 13 Assembly QC ................................................................................................................................................. 14 Gene prediction ............................................................................................................................................ 15 Contamination screening ............................................................................................................................
    [Show full text]
  • Prediction of Drug Interactions with Methadone, Buprenorphine and Oxycodone from in Vitro Inhibition of Metabolism
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Prediction of Drug Interactions with Methadone, Buprenorphine and Oxycodone from In Vitro Inhibition of Metabolism Author(s): David E. Moody, Ph.D. Document No.: 250127 Date Received: July 2016 Award Number: 2011-DN-BX-K532 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this federally funded grant report available electronically. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. February 2016 Research and Development in Forensic Toxicology Prediction of drug interactions with methadone, buprenorphine and oxycodone from in vitro inhibition of metabolism Final Technical Report Submitted electronically to: U.S. Department of Justice Office of Justice Programs National Institute of Justice Prepared by: David E. Moody. Ph.D. Director of the Center for Human Toxicology, and Research Professor of Pharmacology and Toxicology [email protected] / 801-581-5117 NIJ Award Number: 2011-DN-BX-K532 Reporting Period: January 1, 2012 to December 31, 2015 Recipient Organization: University of Utah 75 South 2000 East, Room 222 Salt Lake City, UT 84112-8930 Organizational DUNS: 0090953650000 EIN: 876000525 This document is a research report submitted to the U.S. Department of Justice. This report has not been published by the Department. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S.
    [Show full text]
  • An Important Advance in Anti-Parasitic Therapy
    Am. J. Trop. Med. Hyg., 68(4), 2003, pp. 382–383 Copyright © 2003 by The American Society of Tropical Medicine and Hygiene EDITORIAL NITAZOXANIDE: AN IMPORTANT ADVANCE IN ANTI-PARASITIC THERAPY A. CLINTON WHITE, JR. Infectious Diseases Section, Department of Medicine, Baylor College of Medicine, Houston, Texas The field of anti-parasitic drugs has had a shaky history. maceuticals, Inc. (Marietta, GA) and focused on develop- The major pharmaceutical companies have increasingly fo- ment of the drug for treatment of cryptosporidiosis in ac- cused their drug development efforts on the major markets, quired immunodeficiency syndrome. Controlled trials began with potential annual sales of at least $100 million. This has shortly after the advent of effective anti-retroviral therapies. not worked well for development of anti-parasitic drugs. Most The trials were abandoned due to poor enrollment and the patients develop parasitic infections due to poverty. Thus, Food and Drug Administration rejected an application based while there may be millions of cases in developing countries, on uncontrolled studies. the number able to support the high prices of branded drugs Rather than abandon their efforts, Romark launched an is small. A few new drugs have come into the market. For impressive series of controlled trials. No other agent has example, mefloquine, albendazole, ivermectin, and atova- proven efficacy in the treatment of cryptosporidiosis. How- quone-proguanil have all come to the U.S. market since 1990. ever, a placebo-controlled study of nitazoxanide in cryptospo- However, even this limited number of new drugs is somewhat ridiosis demonstrated significant clinical improvement in deceiving. Mefloquine and atovaquone-proguanil are largely adults and children with mild illness.4 Among malnourished supported by their use in malaria prophylaxis.
    [Show full text]
  • PRESCRIBING INFORMATION These Highlights Do Not Include All the Information Needed to Use ALINIA ______DOSAGE FORMS and STRENGTHS ______Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALINIA _____________ DOSAGE FORMS AND STRENGTHS ______________ safely and effectively. See full prescribing information for ALINIA. ALINIA Tablets: 500 mg (3.1) ALINIA for Oral Suspension: 100 mg/5 mL (3.2) ALINIA® (nitazoxanide) tablets, for oral use ALINIA® (nitazoxanide) for oral suspension ___________________ CONTRAINDICATIONS ___________________ Initial U.S. Approval: 2002 Hypersensitivity (4.1) __________________ _________________ INDICATIONS AND USAGE ___________________ ADVERSE REACTIONS ___________________ ALINIA is an antiprotozoal indicated for the treatment of diarrhea caused by The most common adverse reactions in ≥2% of patients were abdominal pain, Giardia lamblia or Cryptosporidium parvum (1). headache, chromaturia, and nausea (6.1). Limitations of Use: ALINIA has not been shown to be effective for the treatment of diarrhea To report SUSPECTED ADVERSE REACTIONS, contact Romark at caused by C. parvum in HIV-infected or immunodeficient patients (1). 813-282-8544 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. ___________________ ____________________ _______________ DOSAGE AND ADMINISTRATION ______________ DRUG INTERACTIONS ALINIA Tablets should not be administered to pediatric patient 11 years of Competition for binding sites may occur when administered concurrently with age or younger (2.1). other highly plasma protein-bound drugs with narrow therapeutic indices. Dosage for treatment of diarrhea caused by G. lamblia or C. parvum (2.1): Monitor for adverse reactions (7). Age Dosage Duration ______________ USE IN SPECIFIC POPULATIONS _______________ 5 mL of ALINIA for Oral Suspension Pediatric Patients: Safety and efficacy of ALINIA for Oral Suspension in 1-3 years (100 mg nitazoxanide) every 12 hours with food pediatric patients less than one year of age has not been studied (8.4).
    [Show full text]